Blood & Lymphatic Cancer Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY23593
Phase 3 Study of Epcoritamab, Rituximab, and Lenalidomide for First-Line Treatment of Follicular Lymphoma
To assess the efficacy of ER2 compared to CIT in subjects with previously untreated FL. The hypothesis corresponding to the primary objective is that ER2 will improve the CR rate at Month 30 (CR30)/120 weeks when compared to standard of care CIT.
Study InformationSTUDY24084
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)
To compare time to first progression or death (PFS1) with continuous treatment (Arm A) and time to second progression or death (PFS2) with intermittent treatment that is restarted at first progression (Arm B). PFS1 and PFS2 will be defined as follows for patients who achieve complete remission (CR) with induction therapy and are randomized to a maintenance treatment arm: Continuous treatment Arm A: time from randomization until first progression or death from any cause (PFS1). Intermittent treatment Arm B: time from randomization until second progression or death from any cause (PFS2)
Study InformationSTUDY25150
Phase 3 Study of Bomedemstat vs Best Available Therapy for 2L Essential Thrombocythemia
To compare bomedemstat to best available therapy with respect to DCHR. To compare bomedemstat to best available therapy with respect to change in fatigue score based on MFSAF v4.0.
Study Information